Leading Liquid Biopsy Company, Exosome Diagnostics, Appoints Daniel Zabrowski As Board Member

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, the developer of a leading liquid biopsy platform that enables non-invasive diagnosis of disease states, potentially obviating the need for tissue biopsy, has announced the appointment of Dan Zabrowski PhD, as a member of its Board of Directors.

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.